Document is current

Article History

Received: 16 August 2025

Accepted: 21 September 2025

First Online: 22 October 2025

Declarations

:

: A non-identifiable encryption process send data into IQVIA databases, directly from GPs’ computer. IQVIA LPD complies with the European Regulation 679/2016 and the ex-Legislative Decree 196/03 and subsequent modifications. No institutional review board approval was required for the completion of this retrospective observational study that contains no directly identifiable data.

: Silvio Buscemi has received consultancy or speaking fees or research direct or indirect contributions from Novo Nordisk, Eli Lilly, Boehringer, Pfizer, Dompè, Recordati rare diseases, Therascience, and Merieux. Luca Busetto received consulting and advisory Boards fees from Amgen, Boehringer-Ingelheim, Beuno Farmaceutici, Eli-Lilly, Novo Nordisk, Pfizer, Regeneron and Roche and speaker fee from Pronokal and Rhythm Pharma. Uberto Pagotto received consulting and advisory boards fees from Eli-Lilly, Novo Nordisk, Pfizer, Boehringer-Ingelheim, and Sciterion, and speaker fee from Therascience Lignaform, Medinfar, Bruno Farmaceutici, International Medical Press, Rhythm Pharma, Merck, Lilly, and Novo Nordisk. Paolo Sbraccia received payment of honoraria and consulting fees from Boehringer Ingelheim, Chiesi, Novo Nordisk, Eli Lilly, Pfizer, and Roche as a member of advisory boards.Clara Bagatin, Simona Barzaghi, and Valeria Pegoraro have disclosed that they are employees of IQVIA Solutions SRL. The remaining authors declare that they have no competing interests. The authors did not receive payment related to the development of the manuscript.